65,437 trials
End Stage Renal Disease · Sexual Dysfunction, Physiological · Pain
Primary: Change in Pain, Sexual Dysfunction, and Depression Symptoms — -3.12; -3.7; 0.62; 0.71 units on a scale
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Outcome Correspondence to Imaging Results With Fluorine-18 Fluorocholine PET/CT — 100; 100; 100; 0 %PET-positive cases in a given PSA range
Eczema · Dermatitis · Dermal Pruritus
Primary: Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Week 2 — -1.63; -2.17 Score on a Scale — p=<0.001
Major Depressive Disorder
Primary: Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks — -6.3; -6.1 units on a scale — p=0.883
Arterial Thromboembolism · Venous Thromboembolism · Breast Cancer
Primary: Arterial Thromboembolism — 7; 22; 34 participants
Stress Disorder, Post Traumatic
Primary: Clinician-Administered PTSD Scale (CAPS) — 85.3; 88; 82.6 units on a scale
Glaucoma
Primary: Change From Baseline in Intraocular Pressure (IOP) — -8.6; -9.0 mmHg
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or…
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months — 56.5; 57.2 percentage of participants
Radiotherapy-induced Nausea and Vomiting (RINV)
Primary: Complete Control (no Signs of Emesis or Moderate to Severe Nausea and no Use of Rescue Medication) Rate From the Start of Radiotherapy Until 24 Hours After the Third…
Anthrax
Primary: Ratios of Ciprofloxacin Area Under the Curve and Cmax (Day 5/Day 44) — 0.944; 0.887 ratio
Asthma
Primary: Albuterol-induced Change in FEV1 — 0.27; 0.18; 0.32; 0.20 liters
Cystinosis
Primary: The Steady-state White Blood Cell Cystine Levels of RP103 Compared to Cystagon® — 0.5152; 0.4367 nmol ½ Cystine / mg protein — p=0.0001
Post-traumatic Stress Disorders
Primary: SF-36 — 35.2; 39.0; 41.2; 44.5 units on a scale — p=.15
Retinal Disease · Macular Disease
Primary: Total Number of Severe Ocular Adverse Events Related to the Investigational Product — 0 Adverse Events